143 related articles for article (PubMed ID: 12670552)
21. Treatment with low-dose interferon-alpha restores the balance between matrix metalloproteinase-9 and E-cadherin expression in human transitional cell carcinoma of the bladder.
Slaton JW; Karashima T; Perrotte P; Inoue K; Kim SJ; Izawa J; Kedar D; McConkey DJ; Millikan R; Sweeney P; Yoshikawa C; Shuin T; Dinney CP
Clin Cancer Res; 2001 Sep; 7(9):2840-53. PubMed ID: 11555602
[TBL] [Abstract][Full Text] [Related]
22. Serum endostatin levels are elevated in patients with soft tissue sarcoma.
Feldman AL; Pak H; Yang JC; Alexander HR; Libutti SK
Cancer; 2001 Apr; 91(8):1525-9. PubMed ID: 11301401
[TBL] [Abstract][Full Text] [Related]
23. Decreased RECK and Increased EMMPRIN expression in urothelial carcinoma of the bladder are associated with tumor aggressiveness.
Wittschieber D; Stenzinger A; Klauschen F; Stephan C; Jung K; Erbersdobler A; Rabien A
Pathobiology; 2011; 78(3):123-31. PubMed ID: 21613799
[TBL] [Abstract][Full Text] [Related]
24. [Expressions of MMP-2 and COX-2 mRNA in bladder transitional cell carcinoma and their correlation].
Zhang HP; Yu B; Zheng XD; Hu HJ; Gao ZB; Li L; Zhou LF
Zhonghua Nan Ke Xue; 2008 Nov; 14(11):1011-4. PubMed ID: 19102503
[TBL] [Abstract][Full Text] [Related]
25. Role of matrix metalloproteinase-9 in the basement membrane destruction of superficial urothelial carcinomas.
Ozdemir E; Kakehi Y; Okuno H; Yoshida O
J Urol; 1999 Apr; 161(4):1359-63. PubMed ID: 10081908
[TBL] [Abstract][Full Text] [Related]
26. Expression of metalloproteinase-2, metalloproteinase-9, and tissue inhibitor of metalloproteinase-1 in transitional cell carcinoma of upper urinary tract: correlation with tumor stage and survival.
Miyata Y; Kanda S; Nomata K; Hayashida Y; Kanetake H
Urology; 2004 Mar; 63(3):602-8. PubMed ID: 15028476
[TBL] [Abstract][Full Text] [Related]
27. Elevated serum endostatin is associated with poor outcome in patients with non-Hodgkin lymphoma.
Bono P; Teerenhovi L; Joensuu H
Cancer; 2003 Jun; 97(11):2767-75. PubMed ID: 12767089
[TBL] [Abstract][Full Text] [Related]
28. Preoperative plasma levels of interleukin-6 and its soluble receptor predict disease recurrence and survival of patients with bladder cancer.
Andrews B; Shariat SF; Kim JH; Wheeler TM; Slawin KM; Lerner SP
J Urol; 2002 Mar; 167(3):1475-81. PubMed ID: 11832773
[TBL] [Abstract][Full Text] [Related]
29. Noninvasive diagnosis of bladder cancer by detection of matrix metalloproteinases (MMP-2 and MMP-9) and their inhibitor (TIMP-2) in urine.
Eissa S; Ali-Labib R; Swellam M; Bassiony M; Tash F; El-Zayat TM
Eur Urol; 2007 Nov; 52(5):1388-96. PubMed ID: 17466450
[TBL] [Abstract][Full Text] [Related]
30. Correlation of preoperative levels of IGF-I and IGFBP-3 with pathologic parameters and clinical outcome in patients with bladder cancer.
Shariat SF; Kim J; Nguyen C; Wheeler TM; Lerner SP; Slawin KM
Urology; 2003 Feb; 61(2):359-64. PubMed ID: 12597948
[TBL] [Abstract][Full Text] [Related]
31. Urinary type IV collagenase: elevated levels are associated with bladder transitional cell carcinoma.
Margulies IM; Höyhtyä M; Evans C; Stracke ML; Liotta LA; Stetler-Stevenson WG
Cancer Epidemiol Biomarkers Prev; 1992; 1(6):467-74. PubMed ID: 1302559
[TBL] [Abstract][Full Text] [Related]
32. Association of plasma urokinase-type plasminogen activator and its receptor with clinical outcome in patients undergoing radical cystectomy for transitional cell carcinoma of the bladder.
Shariat SF; Monoski MA; Andrews B; Wheeler TM; Lerner SP; Slawin KM
Urology; 2003 May; 61(5):1053-8. PubMed ID: 12736046
[TBL] [Abstract][Full Text] [Related]
33. Prognostic significance of matrix metalloproteinases 2 and 9 in bladder cancer.
Papathoma AS; Petraki C; Grigorakis A; Papakonstantinou H; Karavana V; Stefanakis S; Sotsiou F; Pintzas A
Anticancer Res; 2000; 20(3B):2009-13. PubMed ID: 10928143
[TBL] [Abstract][Full Text] [Related]
34. MMP-3 mRNA and MMP-3 and MMP-1 proteins in bladder cancer: a comparison with clinicopathologic features and survival.
Nakopoulou L; Gakiopoulou H; Zervas A; Giannopoulou I; Constantinides C; Lazaris AC; Liapis H; Kyriakou G; Dimopoulos C
Appl Immunohistochem Mol Morphol; 2001 Jun; 9(2):130-7. PubMed ID: 11396630
[TBL] [Abstract][Full Text] [Related]
35. Excretion of matrix metalloproteinases 2 and 9 in urine is associated with a high stage and grade of bladder carcinoma.
Gerhards S; Jung K; Koenig F; Daniltchenko D; Hauptmann S; Schnorr D; Loening SA
Urology; 2001 Apr; 57(4):675-9. PubMed ID: 11306379
[TBL] [Abstract][Full Text] [Related]
36. Prognostic Value of Soluble Death Receptor Ligands in Patients with Transitional Cell Carcinoma of Bladder.
Ben Bahria-Sediki I; Chebil M; Sampaio C; Martel-Frachet V; Cherif M; Zermani R; Rammeh S; Ben Ammar Gaaied A; Bettaieb A
Urol Int; 2018; 100(4):476-484. PubMed ID: 29719304
[TBL] [Abstract][Full Text] [Related]
37. Validation of circulating MMP-7 level as an independent prognostic marker of poor survival in urinary bladder cancer.
Szarvas T; Jäger T; Becker M; Tschirdewahn S; Niedworok C; Kovalszky I; Rübben H; Ergün S; vom Dorp F
Pathol Oncol Res; 2011 Jun; 17(2):325-32. PubMed ID: 21253919
[TBL] [Abstract][Full Text] [Related]
38. Detection and quantification of soluble intercellular adhesion molecule-1 (sICAM-1) in the serum and urine of patients with bladder cancer.
Shi BB; Goya N; Okuda H; Ryoji O; Nakazawa H; Toma H
Int J Urol; 1998 Jul; 5(4):324-8. PubMed ID: 9712439
[TBL] [Abstract][Full Text] [Related]
39. Urinary levels of monocyte chemo-attractant protein-1 correlate with tumour stage and grade in patients with bladder cancer.
Amann B; Perabo FG; Wirger A; Hugenschmidt H; Schultze-Seemann W
Br J Urol; 1998 Jul; 82(1):118-21. PubMed ID: 9698673
[TBL] [Abstract][Full Text] [Related]
40. [Association of serum decoy receptor 3 protein level with the clinicopathologic features of bladder transitional cell carcinoma].
Wang D; Wang J; Chen G
Nan Fang Yi Ke Da Xue Xue Bao; 2013 Dec; 33(12):1831-2. PubMed ID: 24369256
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
